SIETES :: 93213 citas

Resultados de la búsqueda por MELATONINA REFINAR BÚSQUEDA

1.

Sys J, Van Cleynenbreugel S, Deschodt M, Van der Linden L, Tournoy J. Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review. Eur J Clin Pharmacol 2020;76:marzo. [Ref.ID 103530]

2.

Anónimo. Melatonin for jet lag. Drug Ther Bull 2020;58:enero. [Ref.ID 103526]

3.

Anónimo. Femmes enceintes gênées par un mauvais sommeil. Prescrire 2018;38:354-60. [Ref.ID 102659]

4.

Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol 2017;73:927-35. [Ref.ID 101927]

5.

Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, for the Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016;165:125-33. [Ref.ID 100634]

6.

Wilt TJ, MacDonald R, Brasure M, Olson CM, Carlyle M, Fuchs E, Khawaja IS, Diem S, Koffel E, Ouellette J, Butler M, Kane RL. Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med 2016;165:103-12. [Ref.ID 100633]

7.

Anónimo. Melatonin for sleep problems in children with neurodevelopmental disorders. Drug Ther Bull 2015;53:117-20. [Ref.ID 99604]

8.

Anónimo. Drugs for insomnia. Med Lett Drugs Ther 2015;57:95-8. [Ref.ID 99452]

9.

Furster C, Hallergäck MU. The use of melatonin in Swedish children and adolescents - a register-based study according to age, gender, and medication of ADHD. Eur J Clin Pharmacol 2015;71:877-81. [Ref.ID 99325]

10.

Azparren Andía A, García Romero I. Estrategias para la deprescripción de benzodiazepinas. Boletín de Información Farmacoterapéutica de Navarra 2014;22:1-12. [Ref.ID 98237]

11.

Anónimo. Benzodiacepinas: riesgos y estrategias para su retirada. Boletín Terapéutico Andaluz 2014;29:10-6. [Ref.ID 98202]

12.

Garjón Parra J. Melatonina para los trastornos de sueño . Boletín de Información Farmacoterapéutica de Navarra 2014;22:enero-marzo. [Ref.ID 97709]

13.

Anónimo. Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder. Med Lett Drugs Ther 2014;56:34-5. [Ref.ID 97528]

14.

Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, Frisher M. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014;348:g1996. [Ref.ID 97297]

15.

Anónimo. Manejo del insomnio. Infac: Información Farmacoterapéutica de la Comarca 2013;21:18-25. [Ref.ID 95508]

16.

Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 2013;8:e63773. [Ref.ID 95453]

17.

Jain S, Besag FMC. Does melatonin affect epileptic seizures?. Drug Saf 2013;36:207-15. [Ref.ID 95309]

18.

Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries. Eur J Clin Pharmacol 2013;69:1-10. [Ref.ID 95189]

19.

Anónimo. Tinnitus. Drug Ther Bull 2013;51:20-4. [Ref.ID 94861]

20.

Gringras P, Gamble C, Jones AP, Wiggs L, Williamson PR, Sutcliffe A, Montgomery P, Whitehouse WP, Choonara I, Allport T, Edmond A, Appleton R, on behalf of the MENDS Study Group. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ 2012;345:17. [Ref.ID 94040]